Drugs / Iodine-123
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03498183 | Jan 2019 → May 2025 | thyroid cancer | Nantes University Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iodine-123 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03498183 ↗ |
| Modality | Diagnostic / imaging agent | “Following the injection of MIBI-Tc99m/Iodine-123 , the patients will have a scintigraphy.” NCT03498183 ↗ |